Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines

Tanja D. De Gruijl, Alfons J M Van Den Eertwegh, Herbert M. Pinedo, Rik J. Scheper

Research output: Contribution to journalArticle

Abstract

The field of tumor vaccination is currently undergoing a shift in focus, from individualized tailor-made vaccines to more generally applicable vaccine formulations. Although primarily predicated by financial and logistic considerations, stemming from a growing awareness that clinical development for wide-scale application can only be achieved through backing from major pharmaceutical companies, these new approaches are also supported by a growing knowledge of the intricacies and minutiae of antigen presentation and effector T-cell activation. Here, the development of whole-cell tumor and dendritic cell (DC)-based vaccines from an individualized autologous set-up to a more widely applicable allogeneic approach will be discussed as reflected by translational studies carried out over the past two decades at our laboratories and clinics in the vrije universiteit medical center (VUmc) in Amsterdam, The Netherlands.

Original languageEnglish (US)
Pages (from-to)1569-1577
Number of pages9
JournalCancer Immunology Immunotherapy
Volume57
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

Keywords

  • Allogeneic
  • Autologous
  • Dendritic cell
  • Whole-cell tumor vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines'. Together they form a unique fingerprint.

  • Cite this